Saturday 17 October 2026
Export PPCB’s income statement to Excel — free account
Propanc Biopharma Inc
PPCB Healthcare Biotechnology
In the quarter to June 2026, EPS fell 99.6%, free cash flow fell 1,637.4% and total debt fell 21.4%, each against the same quarter a year earlier.
0.34
0.00
0.00%
Follow PPCB
Target Price Range
Analyst price targets
Free accountTen years at a glance
| Group | Line | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | Trend | 2027e | 2028e | 2029e |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Price, $ | |||||||||||||||
| Price, $ | Low | 2,249,999,872.00 | 97,500,000.00 | 3,000,000.00 | 12,500.00 | 650.00 | 25.00 | 0.36 | 0.01 | 0.01 | 0.33 |
Analyst estimates 2027–2029 Powerpack |
|||
| High | 95,625,003,008.00 | 7,219,999,744.00 | 750,000,000.00 | 87,500,000.00 | 35,000.00 | 2,250.00 | 55.00 | 0.79 | 3,636.50 | 15.38 | |||||
| People | |||||||||||||||
| People | Employees | 2 | 2 | 3 | 3 | 2 | 3 | 2 | 2 | 2 | 2 | ||||
| Revenue/emp, $m | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |||||
| Income, $m | |||||||||||||||
| Income, $m | Revenue | — | — | — | — | — | — | — | — | — | — | ||||
| Gross margin, % | — | — | — | — | — | — | — | — | — | — | |||||
| EBT | (8) | (7) | (6) | (5) | (2) | (3) | (3) | (2) | (59) | (19) | |||||
| EBT margin, % | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |||||
| Net income | (8) | (7) | (6) | (5) | (2) | (3) | (3) | (2) | (59) | (19) | |||||
| Depreciation | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | — | 0 | |||||
| Per share, $ | |||||||||||||||
| Per share, $ | Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | ||||
| Earnings | (2.24) | (178.74) | (10.97) | (192.45) | (999,999,999.00) | (78,125,000.00) | (2,812,500.00) | (31,250.00) | (371.25) | (17.62) | |||||
| Cash flow | (0.58) | (55.27) | (3.92) | (75.19) | (0.38) | (21.06) | (0.64) | (9,351.00) | (2.55) | (5.06) | |||||
| Capex | 0.00 | 0.00 | (0.01) | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |||||
| Free cash flow | (0.58) | (55.27) | (3.93) | (75.19) | (0.38) | (21.06) | (0.64) | (9,351.00) | (2.55) | (5.06) | |||||
| Book value | (1.55) | (171.37) | (8.19) | (148.02) | (1.01) | (44.33) | (1.79) | (37,791.00) | 87.63 | 8.37 | |||||
| Shares, m | 4 | 0 | 1 | 0 | 3 | 0 | 2 | 0 | 0 | 1 | |||||
| Valuation, × | |||||||||||||||
| Valuation, × | P/E | — | — | — | — | — | — | — | — | — | — | ||||
| P/S | — | — | — | — | — | — | — | — | — | — | |||||
| P/B | — | — | — | — | — | — | — | — | — | — | |||||
| EV/Sales | — | — | — | — | — | — | — | — | — | — | |||||
| EV/FCF | — | — | — | — | — | — | — | — | — | — | |||||
| Cash, $m | |||||||||||||||
| Cash, $m | Operating cash flow | (2) | (2) | (2) | (2) | (1) | (1) | (1) | (1) | 0 | (6) | ||||
| Capex | — | — | 0 | — | — | — | — | — | — | 0 | |||||
| Free cash flow | (2) | (2) | (2) | (2) | (1) | (1) | (1) | (1) | 0 | (6) | |||||
| Balance, $m | |||||||||||||||
| Balance, $m | Working capital | (5) | (7) | (4) | (4) | (3) | (3) | (3) | (4) | 3 | 5 | ||||
| Total debt | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | |||||
| Net debt | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | |||||
| Shareholders’ equity | (5) | (7) | (4) | (4) | (3) | (3) | (3) | (4) | 14 | 9 | |||||
| Returns, % | |||||||||||||||
| Returns, % | ROA | (3,318.22) | (8,455.50) | (6,653.26) | (4,735.96) | (4,332.80) | (7,085.23) | (4,403.94) | (3,034.66) | (598.08) | (122.15) | ||||
| ROIC | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | (247.22) | (125.86) | |||||
| ROE | 196.27 | 115.36 | 104.10 | 119.22 | 71.97 | 110.09 | 101.75 | 58.39 | (1,163.68) | (169.86) | |||||
Negative figures in brackets.
Fundamentals updated 6 Oct 2026
Charts ten years each
Propanc Biopharma Inc vs peers in Biotechnology (Q) = latest quarter vs a year earlier
| Company | Market cap | P/E | Fwd P/E | Revenue growth (Q) | EPS growth (Q) | FCF growth (Q) | Gross margin (Q) | EBIT margin (Q) | Compare |
|---|---|---|---|---|---|---|---|---|---|
| KALA KALA BIO, Inc. | $3.7M | — (loss-making) | — (loss-making) | −86.31% (below 0%: shrinking) | n/m | +80.19% (above 0%: growing) | 0.00% | 0.00% | Compare |
| ERNA Ernexa Therapeutics Inc. | $3.5M | — (loss-making) | — (loss-making) | −94.12% (below 0%: shrinking) | n/m | −64.10% (below 0%: shrinking) | 100.00% | 0.00% | Compare |
| PPCB Propanc Biopharma Inc | $3.5M | — (loss-making) | — | — | −99.64% (below 0%: shrinking) | −1,637.42% (below 0%: shrinking) | — | 0.00% | |
| CVKD Cadrenal Therapeutics, Inc. | $3.5M | — (loss-making) | — | — | n/m | +26.24% (above 0%: growing) | 0.00% | 0.00% | Compare |
| IOBTQ IO Biotech, Inc. | $3.5M | — (loss-making) | — | — | n/m | +11.22% (above 0%: growing) | 0.00% | 0.00% | Compare |
| UNBX UNITY Biotechnology, Inc. | $3.4M | — (loss-making) | — (loss-making) | — | n/m | −23.10% (below 0%: shrinking) | 0.00% | 0.00% | Compare |
| LIPO Lipella Pharmaceuticals Inc. | $3.4M | — (loss-making) | — (loss-making) | −36.44% (below 0%: shrinking) | n/m | −41.79% (below 0%: shrinking) | 100.00% | 0.00% | Compare |
| PBLA Panbela Therapeutics Inc. | $3.4M | — (loss-making) | — | — | n/m | +66.23% (above 0%: growing) | — | 0.00% | Compare |
| CMND Clearmind Medicine Inc. | $3.3M | — (loss-making) | — | — | n/m | −77.94% (below 0%: shrinking) | 0.00% | 0.00% | Compare |
| Median of peers | $3.4M | — | — | −86.31% | — | −5.94% | 0.00% | 0.00% |
Propanc Biopharma Inc (PPCB) key facts
- Propanc Biopharma Inc (PPCB) is a Biotechnology company in the Healthcare sector, listed on Nasdaq.
- As of October 16, 2026, PPCB traded at $0.34, a market capitalization of $3.5 million.
- Return on equity was −169.9% and debt-to-equity 0.05.